Trevvi Therapeutics Expands Third Quarter Losses and Changes Development Plans
TRVI Trevi Therapeutics Inc
$15.31 +6.84%
View chart & analysis → - 1Trevvi Therapeutics recorded a net loss of $21.5 million.
- 2Trevvi Therapeutics' third-quarter loss per share of $0.13 represents a 62.5% year-over-year increase in loss compared to the previous year's $0.08 loss.
- 3Management explained that they reached a general consensus with the FDA regarding the development path for the non-IPF ILD program.
So what's the key point?
Trevvi Therapeutics reported a loss of $21.5 million in the third quarter. The company changed its business plans while aligning its drug development direction with a government agency.
Source Earnings Whispers +2 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.